Rockwell Medical, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024
November 12, 2024 at 06:00 am EST
Share
Rockwell Medical, Inc. reported earnings results for the third quarter and nine months ended September 30, 2024. For the third quarter, the company reported sales was USD 28.32 million compared to USD 23.77 million a year ago. Sales was USD 28.32 million compared to USD 23.77 million a year ago. Net income was USD 1.66 million compared to net loss of USD 1.87 million a year ago. Net income was USD 1.66 million compared to net loss of USD 1.87 million a year ago. Basic earnings per share from continuing operations was USD 0.05 compared to basic loss per share from continuing operations of USD 0.07 a year ago. Basic earnings per share from continuing operations was USD 0.05 compared to basic loss per share from continuing operations of USD 0.07 a year ago. Diluted earnings per share from continuing operations was USD 0.04 compared to diluted loss per share from continuing operations of USD 0.07 a year ago.
For the nine months, sales was USD 76.82 million compared to USD 61.52 million a year ago. Sales was USD 76.82 million compared to USD 61.52 million a year ago. Net income was USD 0.276 million compared to net loss of USD 6.93 million a year ago. Net income was USD 0.276 million compared to net loss of USD 6.93 million a year ago. Basic earnings per share from continuing operations was USD 0.01 compared to basic loss per share from continuing operations of USD 0.32 a year ago. Basic earnings per share from continuing operations was USD 0.01 compared to basic loss per share from continuing operations of USD 0.32 a year ago. Diluted earnings per share from continuing operations was USD 0.01 compared to diluted loss per share from continuing operations of USD 0.32 a year ago.
Rockwell Medical, Inc. is a healthcare company. The Company develops, manufactures, commercializes, and distributes a portfolio of hemodialysis products for dialysis providers around the world. The Company operates in the hemodialysis market, which involves the manufacture, sale and distribution of hemodialysis products to hemodialysis clinics, including pharmaceuticals, dialysis concentrates, dialysis kits and other ancillary products used in the dialysis process. It is the supplier of life-sustaining hemodialysis concentrates products to dialysis clinics. Its hemodialysis concentrates products are used to sustain a patient's life by removing toxins and balancing electrolytes in a dialysis patientâs bloodstream. The Company manufactures hemodialysis concentrates at its facilities in Michigan, South Carolina, and Texas, and the Company manufactures its dry acid concentrate mixers at its facility in Iowa.
ROCKWELL MEDICAL, INC. 
